Juniper Pharma Services strengthens capsule capability with Xcelodose
Xcelodose enables Juniper Pharma Services to accurately fill API directly into capsules
Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, has reinforced its early stage capsule filling expertise with the expansion of its Xcelodose powder micro-dosing system as part of its suite of GMP capabilities.
The move by the contract development and manufacturing organisation (CDMO) follows demand from its clients to develop the technique to complement its development services and help get new molecules to Phase I clinical trials quicker.
Xcelodose enables Juniper Pharma Services to accurately fill API directly into capsules in an efficient and automated manner to primarily support first-in-human studies, reduce formulation requirements and minimise drug substance wastage.
Claire Madden-Smith, senior VP at Juniper Pharma Services, said: “We have focused on having a broad range of development capabilities to enable our clients to rapidly access the most appropriate solution to meet their need. The increased usage of Xcelodose is a natural expansion of our manufacturing services.
“Encouragingly, the service is already helping satisfy the growing needs of our clients to get to clinical trials as quickly as possible without compromising on quality. The technique simply allows us to make and supply batches of the drug in capsules for clinic in a much more precise and economical manner.
“Given the shortage of CDMOs in the industry with the capability and expertise to offer Xcelodose in conjunction with associated development and analytical services, we expect a continuation of uptake of our enhanced offering.”
Xcelodose provides the automated processing of API directly into capsules at very low doses and is an ideal tool for highly soluble products and potent molecules. The use of the system removes the requirement for complex formulation development and allows companies to generate invaluable data on a compound in a cost effective way.
With an established track record of helping pharmaceutical companies and emerging biotechs develop new products and platforms, Juniper Pharma Services is able to optimise formulation performance through its science-led approach to projects.
The company has well-established GMP clinical manufacturing capabilities covering topical and oral dosage form products, including the supply of potent compounds and controlled drugs. Since 1997, the CDMO has built a strong reputation in materials characterisation, formulation analysis and IP consultancy.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance